Chantix
Product Images NDC 21695-946

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Chantix (NDC 21695-946). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (B1b95503 1c7a 44e8 B5e0 D50b61db99d5 01)

Chemical structure diagram showing two molecular structures side by side. The right structure includes a bicyclic system with nitrogen atoms, representing a component related to Chantix by Rebel Distributors Corp. The left structure is a molecular schematic with carboxyl and hydroxyl groups, labeled at variable positions with 'R'. The image depicts chemical structural elements without detailed atom labeling.*

FDA Label Image

Figure 1 (B1b95503 1c7a 44e8 B5e0 D50b61db99d5 02)

A bar chart illustrating comparative study data for Chantix at various doses and placebo controls across five studies. The vertical axis represents percentage values from 0% to 60%. Different bars indicate Chantix 0.5 mg, Chantix 1.0 mg, fixed-dose Chantix, bupropion SR, and placebo groups, showing their relative effect sizes with error bars.*

FDA Label Image

Figure 2 (B1b95503 1c7a 44e8 B5e0 D50b61db99d5 03)

A bar chart comparing study results for Chantix at different doses (0.5 mg, 1.0 mg, and 2.0 mg) versus placebo across four studies (Study 2 to Study 5). The vertical axis shows percentages, and error bars indicate variability. Each study group includes the Chantix doses and placebo for comparison.*

FDA Label Image

Figure 3 (B1b95503 1c7a 44e8 B5e0 D50b61db99d5 04)

A line graph showing continuous abstinent percentage over nontreatment follow-up weeks for Chantix 1.0 mg BID versus placebo. The y-axis represents percent continuous abstinent, ranging from 0 to 100, and the x-axis shows nontreatment follow-up intervals in weeks. Two trend lines display comparative abstinence rates over time for Chantix and placebo groups.*

FDA Label Image

Company Logo (B1b95503 1c7a 44e8 B5e0 D50b61db99d5 05)

FDA Label Image

Company Logo (B1b95503 1c7a 44e8 B5e0 D50b61db99d5 06)

FDA Label Image

Chantix 0.5mg/1mg (B1b95503 1c7a 44e8 B5e0 D50b61db99d5 07)

Label for Chantix 0.5 mg / 1 mg tablets showing product details including active ingredient varenicline tartrate equivalence, lot number, and expiration date fields. Distributed by Physician Partner, manufactured by Pfizer Ireland Pharmaceuticals in Germany. Instructions to store at controlled room temperature and keep out of reach of children are included. The label also includes the NDC 21695-945-53 and product ID RC094553.*

FDA Label Image

Chantix 1mg (B1b95503 1c7a 44e8 B5e0 D50b61db99d5 08)

Label for Chantix 1 mg tablets distributed by Physician Partner with product ID RC094656. The label indicates the tablets contain 1.71 mg varenicline tartrate equivalent to 1 mg varenicline free base. Tablets are described as capsular biconvex, light blue, film-coated, with debossing on both sides. Manufacturing is by Pfizer Ireland Pharmaceuticals Dublin, Ireland (Made in Germany). Storage instructions and distributor information are also included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.